receives momentum kicks from the photons in the laser beam, but because every photon that hits the first oscillator also hits the second, the momentum kicks are correlated -they add together, causing fluctuations in the oscillators' separation. However, if it were possible to replace one oscillator with an object that has negative mass, such an object would be pulled, rather than pushed, by the reflected photons (Fig. 1b) . The momentum kicks would be anticorrelated, their effect on the separation would cancel, and the back-action noise on the collective measurement would be avoided.
But this sounds like science fiction. How can one make an object that has negative mass? Although the concept is counter-intuitive, both theory and experiments have shown that oscillators can be engineered to behave as if they have negative mass, without violating any fundamental laws of physics [7] [8] [9] .
Møller et al. have provided the experimental proof that such an oscillator allows quantum back-action noise to be avoided. They created the equivalent of a negative-mass oscillator using the angular-momentum properties of a cloud of caesium atoms. Each electron in an atom carries a form of quantum angular momentum known as spin. Much as a spinning top aligns with a gravitational field, an electron's spin aligns with an applied magnetic field. It then acts like an oscillator -displace its orientation and, in attempting to reorient itself, it oscillates. The authors used a method called optical pumping to invert the orientation of the atoms' combined spin. They then demonstrated that this spin behaves like a negative-mass oscillator.
The authors used laser light to interface this spin oscillator with a conventional mechanical oscillator (see Fig. 2a of the paper 1 ). The latter consisted of a silicon nitride membrane, which the authors placed in a device called an optical cavity to enhance the membrane's interaction with light. Just as in our simple thought experiment, observing the light from the real experiment provides a collective measurement of the two oscillators. Møller et al. showed that this measurement allows quantum back-action noise to be suppressed by 34% with respect to an experiment in which only a conventional mechanical oscillator is used.
Similar levels of back-action-noise suppression were reported last year 10 , also using collective measurements, but in a system of two conventional mechanical oscillators in a superconducting electrical circuit. In both of these quite different experiments, the reduction in back-action noise with respect to standard techniques was relatively modest 1, 10 . Moreover, to achieve any suppression at all, the conventional mechanical oscillators needed to be cooled to temperatures of a few kelvin, limiting potential applications. Nevertheless, these experiments clearly demonstrate that specially engineered collective measurements allow quantum back-action noise to be avoided.
Møller and colleagues' work provides a path towards more-precise sensors of acceleration, force, gravity and any other stimulus that can be coupled to the motion of a mechanical element. In a particularly topical application, their approach could be used in nextgeneration gravitational-wave interferometers, potentially improving our understanding of the early Universe. The authors' experiments are also a key step towards generating atoms and macroscopic mechanical elements that are entangled (correlated in a non-classical way 5 studies have established the feasibility of increasing the immune system's response to tumours by using a vaccination strategy that targets mutant proteins present in tumour cells. In this issue, Ott et al. 6 (page 217) and Sahin et al. 7 (page 222) report the results of phase I clinical trials that assessed a personalized vaccine-based approach to treat people with skin cancer.
The vaccination strategy for triggering a tumour-specific response by immune cells called T cells can consist of the introduction into the body of peptide fragments known as antigens, which are presented to the immune system when bound by proteins of the major histocompatibility complex (MHC). To be successful, cancer vaccines need to meet several key criteria 8 . One of these is the incorporation of tumour-specific antigens that can induce potent immune responses from T cells. Antigens that arise in a tumour from a mutation and that are not normally present in healthy cells (neoantigens) fall into this category.
Another essential aspect of cancer vaccines is the selection of a suitable vaccination approach. Vaccines must effectively deliver materials, such as synthetically generated long peptides, DNA and RNA, that either provide a concentrated source of antigens or can be used by the body to generate antigens. Vaccines should also include a component known as an adjuvant, which provides a general immune stimulus, thereby enabling a more robust response against the tumour than would be generated naturally. For patients who have residual or recurrent tumours after therapy, a step to counteract the suppression of T cells in the cancer microenvironment is another important part of the vaccination strategy.
Ott et al. and Sahin et al. studied patients who had an advanced stage of a common type of skin cancer called melanoma. Many melanomas occur in skin that has been exposed to sunlight, and they are associated with a large number of random DNA mutations in 9 . But these mutations might generate abnormal protein sequences that are not present elsewhere in the body and are therefore potential targets for eliciting or boosting a tumour-specific immune response.
Ott et al. vaccinated six people who had previously undergone surgery to remove a tumour. To create personalized vaccines, the authors sequenced the DNA of tumour cells and healthy cells from each person to identify tumour-specific mutations and determine associated neoantigens. They then used an algorithm to predict which of the neoantigens would bind well to MHC proteins. Each study participant was vaccinated with synthetic long peptides representing up to 20 neoantigens that were specific to each patient's tumour. + helper T cells has been documented, and these cells are also associated with the direct killing of tumour cells 11, 12 . CD4 + helper T cells have an additional role in optimizing the function of CD8 + T cells 13 , and in aiding the generation of CD8 + T cells with a 'memory' capacity 14 that enables a more robust response on a subsequent encounter with a given antigen.
Crucially, the vaccines developed by + T cells, as well as the necessary interactions between these cells to enable optimal T-cell action and memory function. The immune-response data in both studies revealed that the vaccines boosted the number of T cells engaging in an immune response that had previously been observed against certain neoantigens, and also generated T-cell responses against other neoantigens that had not been observed before.
Surprisingly, both studies found that the neoantigens represented in the vaccine that were recognized by CD4 + T cells generated a greater immune response, as assessed by analysis of molecular markers to determine immune cell activation, than was observed for the neoantigens in the vaccine that were recognized by CD8 + T cells. Yet Ott and colleagues' algorithm did not specifically search for neoantigens that were predicted to be presented by MHC class II proteins, and the algorithm used by Sahin et al. was better at predicting the antigens that bind to class I MHC proteins than those that bind to class II.
Of the 6 people who were vaccinated by Ott and colleagues, 4 showed no signs of tumour recurrence in a follow-up period of up to 32 months after vaccination. Tumours were still present in two participants after vaccination, but when these individuals received a treatment that blocked the immunosuppressive PD-1-receptor pathway, their tumours regressed. Of the 13 people who were vaccinated by Sahin and colleagues, 8 remained free of tumours throughout a follow-up period of 12-23 months. The remaining five had tumour relapses; however, complete regression of tumours occurred in one of these people who was given treatment to block the PD-1-receptor pathway. One of the people whose cancer relapsed had a mutation that abolished the expression of MHC class I proteins, indicating a possible mechanism for the tumour to escape from the T-cell response.
The two studies confirm the potential of this type of approach, and improvements in neoantigen prediction will probably allow the even more efficient and precise identification of neoantigens for use in therapeutic vaccines in the future. Although the numbers of people who were treated in these studies were small, both studies indicated potential benefits. For example, following vaccination, fewer episodes of tumour recurrence or tumour migration to other locations in the body (metastasis) occurred than might have been expected, given the clinical history of each patient. Sahin and colleagues noted that participants showed a significantly lower rate of metastasis after vaccination. In the cases in which tumours persisted or regrowth occurred, this could often be combated effectively by treatment that targeted the PD-1-receptor pathway . b, Such immunosuppression can be blocked through treatment that blocks the PD-1-receptor pathway in T cells, enabling them to cause tumour destruction or regression. c, Ott et al. 6 and Sahin et al. 7 report phase I clinical studies that investigated a vaccine-based approach to treat skin cancer. They identified antigens that were expressed on the tumours of individual patients, and generated a personalized vaccine to initiate or strengthen immune responses against these antigens. The authors observed a broadened and boosted immune response against the tumour, with both CD8 + and CD4 + T cells responding to the antigens presented in the vaccine. d, The vaccinations resulted in the destruction or regression of tumours. In some patients, residual tumours could be destroyed by the subsequent use of a treatment to block the PD-1-receptor pathway. It seems probable that vaccination can lead to the destruction of small tumours that have recurred or migrated to other locations in the body (metastases), whereas larger recurrences or metastases might need PD-1-receptor pathway blockade to be completely destroyed.
W I L L I A M S H O T Y K
M ercury, a potentially toxic trace metal, accumulates in the Arctic as a result of human activities -an issue that has broad ecological and societal implications, particularly for indigenous communities that rely on local food sources. But the relative importance of natural versus industrial sources of mercury accumulation has been a subject of debate. On page 201, Obrist et al. 1 provide unambiguous evidence that elevated mercury concentrations in Arctic plants reflect the uptake of gaseous elemental mercury (GEM) from the atmosphere. This insight is crucial to a better understanding of the mercury cycle, and suggests that the Arctic tundra is a major sink for mercury.
The dominant type of mercury in the atmosphere is GEM, a chemically stable form of the element 2 . Analysis 3 of firn (an inter mediate stage between snow and glacial ice that is formed from snow deposited in past seasons) from Greenland showed that atmospheric mercury concentrations increased rapidly after the Second World War, peaked around 1970, and have since declined. Global emissions of mercury to the atmosphere have been falling 4 since 1990 -total emissions have dropped by 20%, and anthropogenic GEM has dropped by 30%.
Although the recent declines in mercury emissions to the atmosphere from human activities are encouraging, they are dwarfed by the two-to threefold decreases in releases of particulate-bound trace elements 5 such as arsenic and chromium between the early 1980s and mid-1990s. The technologies used to remove these elements from the exhausts of smelters and coal-fired power stations are much less efficient at removing mercury 5 . Atmospheric lead emissions over the North Atlantic declined by a factor of five over the same interval 6 , largely because of the elimination of leaded petrol. Seen in this context, anthropogenic mercury emissions to the atmosphere are still cause for concern -especially because bacteria in oxygen-free sediments in lakes and wetlands convert inorganic mercury into methyl mercury, a fat-soluble, organic neurotoxin that becomes concentrated in the food chain 7 .
Mercury transformations at Earth's surface are notoriously complex, involving simultaneous physical, chemical and biological processes. Many years of research were needed to unravel how bacteria convert ionic mercury to methylmercury; this was key to explaining the accumulation of mercury in aquatic organisms. A similar effort was needed to understand the rapid decrease in atmospheric mercury concentrations over the Arctic during polar sunrise (a phenomenon known as an atmospheric mercury depletion event or AMDE), and the concomitant accumulation of mercury in snow 8 . We now know that sunlight creates oxides of bromine (emitted from sea water), which convert mercury from its stable, gaseous form to chemically reactive ionic species that are scavenged by precipitation.
Complex reactions of this sort were initially thought to explain why atmospheric mercury is chemically trapped in the Arctic (Fig. 1) , but it was subsequently found that sunlight also reduces ionic mercury in snow back to its volatile, gaseous form, which is then re-emitted to the air 8 . Moreover, AMDEs are restricted to coastal regions, where marine aerosols are abundant, and so could not explain the anomalous mercury accumulations observed in (Fig. 1) GEM is also produced naturally from sources such as volcanoes. These emissions can be transported to the Arctic, where mercury is contaminating the environment. It was thought that contamination occurs when mercury(ii) is deposited on the Arctic surface through precipitation or through sea-salt-induced processes. Obrist et al. 1 now report that about 70% of mercury deposition in the interior Arctic tundra is derived from GEM. This deposition is enhanced in summer through uptake of GEM by vegetation.
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